Literature DB >> 226882

Treatment of denervated muscle by gangliosides.

M R Caccia, G Meola, C Cerri, L Frattola, G Scarlato, F Aporti.   

Abstract

Short-duration cooling of the nerve to the extensor digitorum longus muscle of the rat in vivo induced partially reversible denervation of the muscle and atrophy in the type 2 muscle fibers. Increases in cyclic adenosine monophosphate, cyclic guanosine monophosphate phosphodiesterase, adenylate cyclase, and guanylate cyclase were observed in the denervated muscle. Treatment with gangliosides of the bovine brain cortex seemed to improve the excitability of the surviving motor units and to encourage recovery of neuromuscular trophic control, but it did not affect the nerve conduction velocity or the contractile properties of the denervated muscle.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 226882     DOI: 10.1002/mus.880020510

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  5 in total

1.  Treatment of peripheral neuropathies.

Authors:  M Hallett; D Tandon; A Berardelli
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-12       Impact factor: 10.154

2.  The Therapeutic Role of Gangliosides in Neurological Disorders.

Authors:  J S Schneider
Journal:  CNS Drugs       Date:  1994-03       Impact factor: 5.749

3.  Gangliosides in rabbit and human skeletal muscle with denervation atrophy.

Authors:  M R Higatsberger; E Auff
Journal:  J Neurol       Date:  1984       Impact factor: 4.849

4.  Sprouting from chicken embryo dorsal root ganglia induced by nerve growth factor is specifically inhibited by affinity-purified antiganglioside antibodies.

Authors:  M Schwartz; N Spirman
Journal:  Proc Natl Acad Sci U S A       Date:  1982-10       Impact factor: 11.205

5.  Immunohistological analyses of neutral glycosphingolipids and gangliosides in normal mouse skeletal muscle and in mice with neuromuscular diseases.

Authors:  M Cacic; K Sostarić; S Weber-Schürholz; J Müthing
Journal:  Glycoconj J       Date:  1995-10       Impact factor: 2.916

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.